Misonix, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Misonix, Inc. Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices, designs, develops, manufactures, and markets innovative products utilizing ultrasound technology to differentiate hard and soft tissue for enhanced clinical outcomes; its core offerings include the BoneScalpel for precise bone sculpting in neurosurgery and spinal procedures, the Nexus ultrasonic surgical aspirator for tumor removal and soft tissue ablation, the SonaWipe and Cordell Replicable Ultrasonic Debridement Systems for advanced wound care including diabetic foot ulcers, and other devices for general surgery, laparoscopic procedures, urology, and plastic surgery applications. The company also provides scientific and industrial ultrasonic equipment such as cleaning systems for medical and dental instruments, the Sonicator liquid processors for laboratory applications including emulsions and suspensions, fluxless soldering systems, spraying systems for industrial uses like painting and optics, and air pollution control solutions including the MYS-TAIRE scrubber for gas, mist, odor, aerosol, and particulate removal in industries such as semiconductors, pharmaceuticals, and food processing. Founded in 1955 as Heat Systems by Howard Alliger and headquartered in Farmingdale, New York, Misonix operates primarily in the United States with international distribution through sales representatives and partners in regions including Europe. In October 2021, Bioventus Inc. Bioventus Inc. completed its $518 million acquisition of Misonix through a cash-and-stock transaction, making Misonix a wholly owned subsidiary and integrating its ultrasonic technologies into Bioventus' regenerative medicine and orthopedics portfolio to accelerate revenue growth, expand salesforces across spine, neurosurgery, and wound care segments, and leverage global infrastructure in markets like the Netherlands, Canada, Germany, and the UK. This strategic combination enhances market reach in hospital, ambulatory surgical center, and office settings, targeting a $15 billion addressable market while driving synergies in product adoption such as BoneScalpel and Nexus, with anticipated annual pre-tax cost savings of $20 million by the end of the second full year post-acquisition.
SHAREHOLDER ALERT: WeissLaw LLP Reminds KRA, HOMB, MSON, and VNE Shareholders About Its Ongoing Investigations
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates HBMD, ACBI, SBKK, MSON; Shareholders are Encouraged to Contact the Firm
Misonix Reports Fourth Quarter and Fiscal Year 2021 Financial Results
MISONIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Misonix, Inc. - MSON
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Misonix, Inc. - MSON
SHAREHOLDER ALERT: WeissLaw LLP Investigates Misonix, Inc.
Bioventus Scoops Up Misonix In $518M Stock & Cash Deal; Raises FY21 Sales Outlook
Misonix Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Misonix, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – MSON
Misonix Appoints Patrick J. Beyer to Board of Directors
Misonix to Participate in Upcoming May and June Virtual Investor Conferences
Misonix, Inc. (MSON) CEO Stavros Vizirgianakis on Q3 2021 Results - Earnings Call Transcript
Misonix to Report Fiscal 2021 Third Quarter Financial Results and Host Conference Call and Webcast on May 6
Misonix Expands Ultrasonic Technology Capabilities to Address the Orthoplastics Market
Misonix Receives Health Canada Approval for neXus
Misonix to Participate in Upcoming March Investor Conferences
Misonix to Participate at Upcoming Investor Conferences
Misonix: Getting To The Bone Of This Bullish Growth Story
Misonix's (MSON) CEO Stavros Vizirgianakis on Q2 2021 Results - Earnings Call Transcript
Misonix Reports Fiscal 2021 Second Quarter Financial Results
Misonix to Report Fiscal 2021 Second Quarter Financial Results and Host Conference Call and Webcast on February 4